玻璃体内注射雷珠单抗对视网膜静脉阻塞继发黄斑水肿的治疗价值评定

Evaluation of the treatment value of intravitreal injection of ranibizumab in the treatment of macular edema secondary to retinal vein occlusion

目的探讨玻璃体内注射雷珠单抗对视网膜静脉阻塞继发黄斑水肿的治疗价值。方法 100例视网膜静脉阻塞继发黄斑水肿患者,按照随机数字表法分为对照组(采取玻璃体内注射曲安奈德治疗)和治疗组(采取玻璃体内注射雷珠单抗治疗),各50例(50眼)。比较两组患者的治疗效果。结果治疗组病情转归率为92.00%(46/50),对照组病情转归率为76.00%(38/50),治疗组患者病情转归率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组矫正后视力水平、中心凹情况、眼压情况比较,差异无统计学意义(P>0.05);治疗6个月后,治疗组矫正后视力水平、中心凹厚度改善优于治疗前及对照组,差异有统计学意义(P<0.05),治疗组治疗前后眼压情况比较,差异无统计学意义(P>0.05),而对照组眼压则明显升高,差异有统计学意义(P<0.05)。治疗组药物不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论玻璃体内注射雷珠单抗对视网膜静脉阻塞继发黄斑水肿的治疗价值高,可有效改善患者视力和降低中心凹厚度,且对眼压无明显不良影响,安全性高,值得推广应用。

Objective To discuss the treatment value of intravitreal injection of ranibizumab in the treatment of macular edema secondary to retinal vein occlusion.Methods A total of 100 patients with macular edema secondary to retinal vein occlusion were divided by random number table method into control group（intravitreal injection of triamcinolone acetonide） and treatment group（intravitreal injection of ranibizumab）,with 50 cases（50 eyes） in each group.The treatment effect in two groups was compared.Results The treatment group had disease conversion rate as 92.00%（46/50）,which was 76.00%（38/50） in the control group.The treatment group had higher disease conversion rate than the control group,and the difference was statistically significant（P〈0.05）.Before treatment,both groups had no statistically significant difference in corrected visual acuity level,central fovea and intraocular pressure situation（P〈0.05）.After 6 months of treatment,the treatment group had better corrected visual acuity level and central fovea improvement than before treatment and the control group,and their difference was statistically significant（P〈0.05）.The treatment group had no statistically significant difference in intraocular pressure before and after treatment（P〈0.05）,while the control group had obviously higher intraocular pressure,and the difference was statistically significant（P〈0.05）.The treatment group had lower incidence of adverse drug reactions than the control group,and the difference was statistically significant（P〈0.05）.Conclusion Intravitreal injection of ranibizumab shows high value in the treatment of macular edema secondary to retinal vein occlusion,and can effectively improve visual acuity and reduce the thickness of central fovea without obvious adverse effect on intraocular pressure.It has high safety and is worth popularizing and applying.